# US 2020/0399615 A1 · Enhanced adoptive cell therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399615 A1
- Document ID: US20200399615A1
- Status: Published application
- Kind: A1
- Application number: 17/010,644
- Filed: 2020-09-02
- Published: 2020-12-24
- Earliest claimed: 2013-04-18
- Assignees: Tilt Biotherapeutics Oy
- Applicants: TILT Biotherapeutics Oy
- Inventors: Akseli Hemminki; Markus Vähä-Koskela; Siri Tähtinen; Vincenzo Cerullo
- Web page: https://patentgrep.com/patent/US20200399615A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 35/761: Adenovirus
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/42: Cancer antigens
- C07K 14/472: {Complement proteins, e.g. anaphylatoxin, C3a, C5a}
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/55: IL-2
- C07K 14/56: IFN-alpha
- C07K 14/565: IFN-beta
- C07K 14/57: IFN-gamma
- C12N 15/86: Viral vectors
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/57: Skin; melanoma
- C12N 2710/10032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/10041: Use of virus, viral particle or viral elements as a vector
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.

## Claims

### Claim 1

A serotype 3 (Ad3) oncolytic adenoviral vector comprising: a deletion in the E3 area and an exogenous or tumor specific promoter for expression of a transgene in the place of the deleted area of E3, wherein said transgene is a cytokine.

### Claim 2 (depends on 1)

The oncolytic adenoviral vector according to claim 1, wherein said cytokine is selected from a group consisting of interferon alpha, interferon beta, interferon gamma, complement C5a, IL-2, TNFalpha, CD40L, IL12, IL-23, IL15, IL17, CCL1, CCL11, CCL12, CCL13, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23-1, CCL23-2, CCL24, CCL25-1, CCL25-2, CCL26, CCL27, CCL28, CCL3, CCL3L1, CCL4, CCL4L1, CCL5 (=RANTES), CCL6, CCL7, CCL8, CCL9, CCR10, CCR2, CCR5, CCR6, CCR7, CCR8, CCRL1, CCRL2, CX3CL1, CX3CR, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCR1, CXCR2, CXCR4, CXCR5, CXCR6, CXCR7 and XCL2.

### Claim 3 (depends on 1)

The oncolytic adenoviral vector according to claim 1, wherein said transgene is cytokine CD40L.

### Claim 4 (depends on 3)

The oncolytic adenoviral vector according to claim 3, wherein the vector comprises hTERT promoter for expression of E1A and CMV promoter for expression of CD40L in the E3 region.

### Claim 5 (depends on 1)

The oncolytic adenoviral vector according to claim 1, wherein the vector codes for two or more cytokines.

### Claim 6 (depends on 5)

The oncolytic adenoviral vector according to claim 5, wherein the vector comprises an internal ribosomal entry site (IRES) or a ribosome shunt site 2A between the two transgenes.

### Claim 7 (depends on 1)

The oncolytic adenoviral vector according to claim 1, wherein the vector comprises a deletion in the E3 area affecting E3 9 kDa, E3 10.2 kDa, E3 15.2 kDa and E3 15.3 kDa.

### Claim 8 (depends on 1)

The oncolytic adenoviral vector according to claim 1, wherein the promoter for expression of a transgene in the E3 region is the CMV or E2F promoter.
